Pharmaceutical manufacturers can protect products against counterfeiting and patients against potential health risks.

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences.

SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks. DNA markers are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law.

In the flow: A key acquisition, new blood-analyzing tech and critical Medicare/Medicaid reimbursements for T-cell therapies have Applied DNA Sciences and 2018 spinoff LineaRX pumped up.

By GREGORY ZELLER //

Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its first corporate acquisition.

LineaRX, a subsidiary of Applied DNA Sciences, has acquired the physical assets and intellectual property of Vitatex Inc., a private biotech with close ties to Stony Brook University and a patented method of isolating Invasive Circulating Tumor Cells in standard blood samples – spotting metastatic cells before primary tumors are usually visible, allowing for a range of preventative-care options.

Company to Hold Conference Call and Webcast Today, Tuesday, August 13, 2019 at 4:30 PM EST.

STONY BROOK, N.Y. – August 13, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), announced consolidated financial results for the fiscal 2019 third quarter ended June 30, 2019. “Our fiscal third quarter performance reflects our continuing abilities to monetize our molecular taggant technology and our diagnostic and therapeutic platforms while also realigning our cost structure and reorienting our sales and business development efforts to support new opportunities,” said Dr. James A. Hayward, chairman, president and CEO of Applied DNA. “Revenues increased over 100% this quarter over the same period last fiscal year and increased 164% quarter over quarter, supplemented by the receipt of a $1 million cash payment under the terms of our exclusive licensing agreement with TheraCann International Benchmark Corporation (TheraCann).”

“After the close of the quarter we received a written delisting notice from Nasdaq regarding our non-compliance with the requirements for a $1.00 bid price and $35 million market value of listed securities.  We are diligently working to comply with all applicable requirements for continued listing on Nasdaq and we intend to submit a plan to that effect to the NASDAQ Hearings Panel as part of the hearing process,” continued Dr. Hayward. “As part of our plan, we secured a non-binding term sheet from TheraCann for the outstanding $4 million balance under our licensing agreement in the form of $4 million in convertible preferred stock as well as an incremental $1 million convertible note.  We also raised $1.5 million through a convertible note offering, which increases our current convertible notes outstanding to approximately $3.7 million.  If any portion of these notes were to convert into common stock, it would increase our equity as a further step towards facilitating Nasdaq compliance.  We are engaged in Nasdaq’s appeal process, and I am pleased to report that we have secured a hearing for September 19, 2019 that allows us additional time to execute on the balance of our plan. However, we can not provide assurance that we will be successful in our NASDAQ appeal.”

Concluded, Dr. Hayward, “As we projected last quarter, our growth is coming from cannabis, textiles and biotherapeutics. Looking ahead, we remain focused on growth supported by these business verticals. TheraCann’s ETCH^™ BioTrace solution powered by our tagging platform is attracting the attention of large cannabis players. We will soon launch our CertainT^® brand into the cotton apparel market. Initial product from our recently completed tagging program for Egyptian cotton is being used to build demand among brands and manufacturers. Our LineaRx subsidiary is increasingly being viewed within the biotech industry as a cleaner, higher-performing alternative to plasmid DNA production that is converting to increased order-flow.  We have a burgeoning pipeline and growing scientific and intellectual property assets following the recent acquisition by LineaRx of the  assets and IP of Vitatex, Inc. that further broaden our platform’s applicability in the potentially high-reward cancer diagnostic and therapeutic spaces. Just last week we submitted to the NIH our application for a 3-year, approximately $4 million SBIR Phase IIb grant to be matched with funding being sought from commercial 3rd parties, that, if granted, will fund the full commercialization of the Vitatex platform for early detection of non-hematologic cancers.”

Fiscal Third Quarter 2019 Financial Results:

• Revenues increased 102% for the third quarter of fiscal 2019 to $2.1 million, compared with $1.0 million reported in the second quarter of fiscal 2018, and increased 164% from the $778 thousand reported in the second fiscal quarter ended March 31, 2019. The increase in revenues was due primarily to an increase in revenue from a licensing agreement in the cannabis industry of $1 million.
• Total operating expenses decreased to $3.2 million for the second fiscal quarter of 2019, compared with $3.6 million in the prior fiscal year’s second quarter. This decrease is primarily attributable to approximately a $409 thousand decrease in payroll, due to a realignment of the sales force and reductions in overall headcount. This decrease in payroll was offset by an increase in legal and professional fees.
• Net loss for the quarter ended June 30, 2019 was $1.5 million, or $0.04 per share, compared with a net loss of $2.9 million, or $0.10 per share, for the quarter ended June 30, 2018 and a net loss of $2.7 million, or $0.08 per share, for the quarter ended March 31, 2018.
• Excluding non-cash expenses, Adjusted EBITDA was negative $1.2 million and a negative $2.5 million for the quarters ended June 30, 2019 and 2018, respectively. See below for information regarding non-GAAP measures.

Nine-Month Financial Highlights

• Revenues for the first nine months of fiscal 2019 totaled $3.7 million, an increase of 37% from $2.7 million from the same period in the prior fiscal year. The increase in revenues was due to an increase in service revenues of $1.4 million, or 92%, offset by a decrease in product revenues of $344 thousand, or 28%. The increase in service revenue was attributable to an increase in revenue of $1 million from the licensing agreement in the cannabis industry, as well as increases of $140 thousand for a pre-commercial feasibility project under the cooperation agreement with TheraCann entered into during 2018,  $51 thousand for the government contract award and $143 thousand from  pre-commercial pilots within the textile industry.
• Effective October 1, 2018, the Company was required to adopt Accounting Standards Update (ASU; the “Update”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), utilizing the modified retrospective method. Had the Company not adopted the Update, the Company would have recognized additional revenue of approximately $851 thousand during the first nine months of fiscal 2019. This amount was primarily comprised of the recognition of $766 thousand during the nine months periods ended June 30, 2019, under a $1.15 million cotton order shipped in June 2018, with extended payment terms. The total cumulative impact of the Update that was recorded to opening retained earnings in fiscal 2019 was approximately $494 thousand. See Cumulative Effect Adjustment and the Impact on Current Period Financial Statements of Adopting Topic 606 attached.
• Operating expenses for the nine months ended June 30, 2019 increased by $486 thousand or 5% for the same period last fiscal year. The increase is primarily attributable to an increase in stock-based compensation and legal and professional fees, offset by a decrease in payroll of $659 thousand.
• Net loss for the nine months ended June 30, 2019 was $7.4 million or $0.21 per share, compared with a net loss of $8.2 million or $0.28 per share for the nine months ended June 30, 2018.
• Excluding non-cash expenses and interest, Adjusted EBITDA for the nine months ended June 30, 2019 was a negative $6.1 million as compared to a negative $7.6 million for the same period in the prior fiscal year. See below for information regarding non-GAAP measures.

Fiscal Third Quarter 2019 Conference Call Information
The Company will hold a conference call and webcast to discuss its fiscal third quarter-end 2019 results on Tuesday, August 13, 2019 at 4:30 PM ET. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors’ questions on the Q&A portion of the call, due to the large number of expected participants, not all questions may be answered.

To Participate:

• Participant Toll Free:1-844-887-9402
• Participant Toll: 1-412-317-6798
• Please ask to be joined to the Applied DNA Sciences call

Live webcast: https://services.choruscall.com/links/apdn190808.html

Replay (available 1 hour following the conclusion of the live call through August 21, 2019):

• Participant Toll Free: 1-877-344-7529
• Participant Toll: 1-412-317-0088
• Participant Passcode: 10133063
• Webcast replay: https://services.choruscall.com/links/apdn190808.html

For those investors unable to attend the live call, a copy of management’s PowerPoint presentation will be available for review under the ‘Events and Presentations’ section of the company’s Investor Relations web site: https://adnasprod.wpengine.com/molecular-based-security/investors/

Information about Non-GAAP Financial Measures
As used herein, “GAAP” refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

“EBITDA”- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

“Adjusted EBITDA”- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, shifting enforcement priorities of US federal laws relating to cannabis, ability to maintain its NASDAQ listing in light of delisting notices received and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, 212-838-3777, LHA Investor Relations, shurry@lhai.com

APPLIED DNA SCIENCES, INC. CONSOLIDATED BALANCE SHEETS

	June 30, 2019 (unaudited)	September 30, 2018
ASSETS
Current assets:
Cash and cash equivalents	507,146	1,659,564
Accounts receivable, net	243,557	1,485,938
Inventories	309,746	221,369
Prepaid expenses and other current assets	544,509	635,174
Total current assets	1,604,958	4,002,045
Property and equipment, net	265,295	419,774
Other assets:
Deposits	62,375	62,325
Goodwill	285,386	285,386
Intangible assets, net	767,129	864,203
Total Assets	2,985,143	5,633,733
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	1,171,172	965,167
Deferred revenue	802,585	1,856,693
Total current liabilities	1,973,757	2,821,860
Long-term accrued liabilities	584,246	470,739
Secured convertible notes payable	2,215,668	1,586,631
Total liabilities	4,773,671	4,879,230
Commitments and contingencies
Stockholders’ (Deficit) Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2019 and September 30, 2018	–	–
Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2019 and September 30, 2018	–	–
Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2019 and September 30, 2018	–	–
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 38,327,057 and 30,112,057 shares issued and outstanding as of June 30, 2019 and September 30, 2018, respectively	38,327	30,112
Additional paid in capital	253,444,993	249,090,474
Accumulated deficit	(255,271,848)	(248,366,083)
Total stockholders’ (deficit) equity	(1,788,528)	754,503
Total Liabilities and Stockholders’ (Deficit) Equity	2,985,143	5,633,733

APPLIED DNA SCIENCES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

	Three Months Ended June 30, 2019	Three Months Ended June 30, 2018	Nine Months Ended June 30, 2019	Nine Months Ended June 30, 2018
Revenues:
Product revenues	392,599	393,758	885,736	1,230,232
Service revenues	1,660,858	622,597	2,830,511	1,477,746
Total revenues	2,053,457	1,016,355	3,716,247	2,707,978
Cost of revenues	270,883	252,562	557,508	956,155
Operating expenses:
Selling, general and administrative	2,407,223	2,882,158	8,018,516	7,471,917
Research and development	719,668	625,006	2,080,610	2,034,886
Depreciation and amortization	87,315	122,999	320,039	425,927
Total operating expenses	3,214,206	3,630,163	10,419,165	9,932,730
LOSS FROM OPERATIONS	(1,431,632)	(2,866,370)	(7,260,426)	(8,180,907)
Other income (expense):
Interest (expense) income, net	(38,177)	–	(107,206)	–
Other expense	(8,102)	(21,353)	(31,356)	(36,738)
Loss before provision for income taxes
Provision for income taxes	—	—	—	—
NET LOSS	(1,477,911)	(2,887,723)	(7,398,988)	(8,217,645)
Net loss per share-basic and diluted	(0.04)	(0.10)	(0.21)	(0.28)
Weighted average shares outstanding-
Basic and diluted	38,113,391	30,112,057	34,970,862	29,290,555

APPLIED DNA SCIENCES, INC. CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA (unaudited)

	Three Months Ended June 30, 2019	Three Months Ended June 30, 2018	Nine Months Ended June 30, 2019	Nine Months Ended June 30, 2018
Net Loss	$     (1,477,911)	$      (2,887,723)	$      (7,398,988)	$      (8,217,645)
Interest expense (income), net	38,177	–	107,206	–
Depreciation and amortization	87,315	122,999	320,039	425,927
Stock based compensation expense (income)	154,304	238,738	911,642	184,806
Bad debt expense	–	3,434	(8,633)	20,552
Total non-cash items	279,796	365,171	1,330,254	631,285
Consolidated Adjusted EBITDA (loss)	$    (1,198,115)	$       (2,522,552)	$     (6,068,734)	$     (7,586,360)

	Three months ended June 30, 2019 (unaudited) prior U.S. GAAP	Three months ended June 30, 2019 (unaudited) Topic 606 impact	Three months ended June 30, 2019 (unaudited) as reported
Statement of Operations
Revenues
Product	392,599	–	392,599
Service	1,681,065	(20,207)	1,660,858
Total revenues	2,073,664	(20,207)	2,053,457
Cost of revenues	270,883	–	270,883
Loss from operations	(1,411,425)	(20,207)	(1,431,632)

 

	Nine months ended June 30, 2019 (unaudited) prior U.S. GAAP	Nine months ended June 30, 2019 (unaudited) Topic 606 impact	Nine months ended June 30, 2019 (unaudited) as reported
Statement of Operations
Revenues
Product	1,651,928	(766,192)	885,736
Service	2,914,956	(84,445)	2,830,511
Total revenues	4,566,884	(850,637)	3,716,247
Cost of revenues	564,176	(6,668)	557,508
Loss from operations	(6,416,455)	(843,971)	(7,260,426)
Assets
Prepaids and other current assets	551,178	(6,669)	544,509
Liabilities and stockholder’s equity
Deferred Revenue	452,139	350,446	802,585
Accumulated Deficit	(254,921,402)	(350,446)	(255,271,848)

A new forensic authentication feature for pharmaceutical labels is offered by Schreiner MediPharm in cooperation with Applied DNA Sciences: SigNature® DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect their products against counterfeiting and patients against potential health risks. DNA markers are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law.

A secure supply chain is indispensable in the pharmaceutical industry. If counterfeit medicines are put into circulation this may result in claims for damages by affected patients. Pharmaceutical manufacturers are able to counteract such illegal practices by providing their original products with forensic anti-counterfeiting features such as DNA markers. Using conventional printing techniques, Schreiner MediPharm flexibly and invisibly integrates this high-security technology from Applied DNA Sciences into existing label designs.

SigNature is based on DNA markers which are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law

Schreiner MediPharm now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks. DNA markers are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law.

STONY BROOK, N.Y. – August 13, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), announced consolidated financial results for the fiscal 2019 third quarter ended June 30, 2019. “Our fiscal third quarter performance reflects our continuing abilities to monetize our molecular taggant technology and our diagnostic and therapeutic platforms while also realigning our cost structure and reorienting our sales and business development efforts to support new opportunities,” said Dr. James A. Hayward, chairman, president and CEO of Applied DNA. “Revenues increased over 100% this quarter over the same period last fiscal year and increased 164% quarter over quarter, supplemented by the receipt of a $1 million cash payment under the terms of our exclusive licensing agreement with TheraCann International Benchmark Corporation (TheraCann).”“After the close of the quarter we received a written delisting notice from Nasdaq regarding our non-compliance with the requirements for a $1.00 bid price and $35 million market value of listed securities.  We are diligently working to comply with all applicable requirements for continued listing on Nasdaq and we intend to submit a plan to that effect to the NASDAQ Hearings Panel as part of the hearing process,” continued Dr. Hayward. “As part of our plan, we secured a non-binding term sheet from TheraCann for the outstanding $4 million balance under our licensing agreement in the form of $4 million in convertible preferred stock as well as an incremental $1 million convertible note.  We also raised $1.5 million through a convertible note offering, which increases our current convertible notes outstanding to approximately $3.7 million.  If any portion of these notes were to convert into common stock, it would increase our equity as a further step towards facilitating Nasdaq compliance.  We are engaged in Nasdaq’s appeal process, and I am pleased to report that we have secured a hearing for September 19, 2019 that allows us additional time to execute on the balance of our plan. However, we can not provide assurance that we will be successful in our NASDAQ appeal.”Concluded, Dr. Hayward, “As we projected last quarter, our growth is coming from cannabis, textiles and biotherapeutics.  Looking ahead, we remain focused on growth supported by these business verticals. TheraCann’s ETCH^TM BioTrace solution powered by our tagging platform is attracting the attention of large cannabis players. We will soon launch our CertainT^â brand into the cotton apparel market. Initial product from our recently completed tagging program for Egyptian cotton is being used to build demand among brands and manufacturers. Our LineaRx subsidiary is increasingly being viewed within the biotech industry as a cleaner, higher-performing alternative to plasmid DNA production that is converting to increased order-flow.  We have a burgeoning pipeline and growing scientific and intellectual property assets following the recent acquisition by LineaRx of the  assets and IP of Vitatex, Inc. that further broaden our platform’s applicability in the potentially high-reward cancer diagnostic and therapeutic spaces. Just last week we submitted to the NIH our application for a 3-year, approximately $4 million SBIR Phase IIb grant to be matched with funding being sought from commercial 3rd parties, that, if granted, will fund the full commercialization of the Vitatex platform for early detection of non-hematologic cancers.”Fiscal Third Quarter 2019 Financial Results:

• Revenues increased 102% for the third quarter of fiscal 2019 to $2.1 million, compared with $1.0 million reported in the second quarter of fiscal 2018, and increased 164% from the $778 thousand reported in the second fiscal quarter ended March 31, 2019. The increase in revenues was due primarily to an increase in revenue from a licensing agreement in the cannabis industry of $1 million.
• Total operating expenses decreased to $3.2 million for the second fiscal quarter of 2019, compared with $3.6 million in the prior fiscal year’s second quarter. This decrease is primarily attributable to approximately a $409 thousand decrease in payroll, due to a realignment of the sales force and reductions in overall headcount. This decrease in payroll was offset by an increase in legal and professional fees.
• Net loss for the quarter ended June 30, 2019 was $1.5 million, or $0.04 per share, compared with a net loss of $2.9 million, or $0.10 per share, for the quarter ended June 30, 2018 and a net loss of $2.7 million, or $0.08 per share, for the quarter ended March 31, 2018.
• Excluding non-cash expenses, Adjusted EBITDA was negative $1.2 million and a negative $2.5 million for the quarters ended June 30, 2019 and 2018, respectively. See below for information regarding non-GAAP measures.

Nine-Month Financial Highlights:

• Revenues for the first nine months of fiscal 2019 totaled $3.7 million, an increase of 37% from $2.7 million from the same period in the prior fiscal year. The increase in revenues was due to an increase in service revenues of $1.4 million, or 92%, offset by a decrease in product revenues of $344 thousand, or 28%. The increase in service revenue was attributable to an increase in revenue of $1 million from the licensing agreement in the cannabis industry, as well as increases of $140 thousand for a pre-commercial feasibility project under the cooperation agreement with TheraCann entered into during 2018,  $51 thousand for the government contract award and $143 thousand from  pre-commercial pilots within the textile industry.
• Effective October 1, 2018, the Company was required to adopt Accounting Standards Update (ASU; the “Update”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), utilizing the modified retrospective method. Had the Company not adopted the Update, the Company would have recognized additional revenue of approximately $851 thousand during the first nine months of fiscal 2019. This amount was primarily comprised of the recognition of $766 thousand during the nine months periods ended June 30, 2019, under a $1.15 million cotton order shipped in June 2018, with extended payment terms. The total cumulative impact of the Update that was recorded to opening retained earnings in fiscal 2019 was approximately $494 thousand. See Cumulative Effect Adjustment and the Impact on Current Period Financial Statements of Adopting Topic 606 attached.
• Operating expenses for the nine months ended June 30, 2019 increased by $486 thousand or 5% for the same period last fiscal year. The increase is primarily attributable to an increase in stock-based compensation and legal and professional fees, offset by a decrease in payroll of $659 thousand.
• Net loss for the nine months ended June 30, 2019 was $7.4 million or $0.21 per share, compared with a net loss of $8.2 million or $0.28 per share for the nine months ended June 30, 2018.
• Excluding non-cash expenses and interest, Adjusted EBITDA for the nine months ended June 30, 2019 was a negative $6.1 million as compared to a negative $7.6 million for the same period in the prior fiscal year. See below for information regarding non-GAAP measures.

Fiscal Third Quarter 2019 Conference Call InformationThe Company will hold a conference call and webcast to discuss its fiscal third quarter-end 2019 results on Tuesday, August 13, 2019 at 4:30 PM ET. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors’ questions on the Q&A portion of the call, due to the large number of expected participants, not all questions may be answered.To Participate:

• Participant Toll Free:1-844-887-9402
• Participant Toll: 1-412-317-6798
• Please ask to be joined to the Applied DNA Sciences call

Live webcast: https://services.choruscall.com/links/apdn190808.htmlReplay (available 1 hour following the conclusion of the live call through August 21, 2019):

• Participant Toll Free: 1-877-344-7529
• Participant Toll: 1-412-317-0088
• Participant Passcode: 10133063
• Webcast replay: https://services.choruscall.com/links/apdn190808.html

For those investors unable to attend the live call, a copy of management’s PowerPoint presentation will be available for review under the ‘Events and Presentations’ section of the company’s Investor Relations web site: https://adnas.com/molecular-based-security/investors/Information about Non-GAAP Financial MeasuresAs used herein, “GAAP” refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.“EBITDA”- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.“Adjusted EBITDA”- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.About Applied DNA SciencesApplied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.Forward-Looking StatementsThe statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, shifting enforcement priorities of US federal laws relating to cannabis, ability to maintain its NASDAQ listing in light of delisting notices received and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.  Investor contact: Sanjay M. Hurry, 212-838-3777, LHA Investor Relations, shurry@lhai.comMedia contact:    Susan Forman, Dian Griesel Int’l., 212-825-3210, sforman@dgicomm.comWeb: www.adnas.comTwitter: @APDN

		June 30, 2019 (unaudited)					September 30, 2018
ASSETS
Current assets:
Cash and cash equivalents		$	507,146				$		1,659,564
Accounts receivable, net			243,557						1,485,938
Inventories			309,746						221,369
Prepaid expenses and other current assets			544,509						635,174
Total current assets			1,604,958						4,002,045
Property and equipment, net			265,295						419,774
Other assets:
Deposits			62,375						62,325
Goodwill			285,386						285,386
Intangible assets, net			767,129						864,203
Total Assets		$	2,985,143				$		5,633,733
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	1,171,172				$		965,167
Deferred revenue			802,585						1,856,693
Total current liabilities			1,973,757						2,821,860
Long-term accrued liabilities			584,246						470,739
Secured convertible notes payable			2,215,668						1,586,631
Total liabilities			4,773,671						4,879,230
Commitments and contingencies
Stockholders’ (Deficit) Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2019 and September 30, 2018			–						–
Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2019 and September 30, 2018			–						–
Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2019 and September 30, 2018			–						–
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 38,327,057 and 30,112,057 shares issued and outstanding as of June 30, 2019 and September 30, 2018, respectively			38,327						30,112
Additional paid in capital			253,444,993						249,090,474
Accumulated deficit				(255,271,848	)				(248,366,083)
Total stockholders’ (deficit) equity			(1,788,528		)				754,503
Total Liabilities and Stockholders’ (Deficit) Equity		$	2,985,143				$		5,633,733

		Three Months Ended June 30,										Nine Months Ended June 30,
		2019				2018							2019				2018
Revenues:
Product revenues		$	392,599			$	393,758						$	885,736			$	1,230,232
Service revenues			1,660,858				622,597							2,830,511				1,477,746
Total revenues			2,053,457				1,016,355							3,716,247				2,707,978
Cost of revenues			270,883				252,562							557,508				956,155
Operating expenses:
Selling, general and administrative			2,407,223				2,882,158							8,018,516				7,471,917
Research and development			719,668				625,006							2,080,610				2,034,886
Depreciation and amortization			87,315				122,999							320,039				425,927
Total operating expenses			3,214,206				3,630,163							10,419,165				9,932,730
LOSS FROM OPERATIONS			(1,431,632)				(2,866,370)							(7,260,426)				(8,180,907)
Other income (expense):
Interest (expense) income, net			(38,177)				–							(107,206)				–
Other expense			(8,102)				(21,353)							(31,356)				(36,738)
Loss before provision for income taxes
Provision for income taxes			—				—							—				—
NET LOSS		$	(1,477,911)			$	(2,887,723)						$	(7,398,988)			$	(8,217,645)
Net loss per share-basic and diluted		$	(0.04)			$	(0.10)						$	(0.21)			$	(0.28)
Weighted average shares outstanding-
Basic and diluted			38,113,391				30,112,057							34,970,862				29,290,555

		Three Months Ended June 30,										Nine Months Ended June 30,
		2019				2018							2019				2018
Revenues:
Product revenues		$	392,599			$	393,758						$	885,736			$	1,230,232
Service revenues			1,660,858				622,597							2,830,511				1,477,746
Total revenues			2,053,457				1,016,355							3,716,247				2,707,978
Cost of revenues			270,883				252,562							557,508				956,155
Operating expenses:
Selling, general and administrative			2,407,223				2,882,158							8,018,516				7,471,917
Research and development			719,668				625,006							2,080,610				2,034,886
Depreciation and amortization			87,315				122,999							320,039				425,927
Total operating expenses			3,214,206				3,630,163							10,419,165				9,932,730
LOSS FROM OPERATIONS			(1,431,632)				(2,866,370)							(7,260,426)				(8,180,907)
Other income (expense):
Interest (expense) income, net			(38,177)				–							(107,206)				–
Other expense			(8,102)				(21,353)							(31,356)				(36,738)
Loss before provision for income taxes
Provision for income taxes			—				—							—				—
NET LOSS		$	(1,477,911)			$	(2,887,723)						$	(7,398,988)			$	(8,217,645)
Net loss per share-basic and diluted		$	(0.04)			$	(0.10)						$	(0.21)			$	(0.28)
Weighted average shares outstanding-
Basic and diluted			38,113,391				30,112,057							34,970,862				29,290,555

	Three Months Ended June 30,		Nine Months Ended June 30,
	2019	2018	2019	2018
Net Loss	$(1,477,911)	$(2,887,723)	$(7,398,988)	$(8,217,645)
Interest expense (income), net	38,177	–	107,206	–
Depreciation and amortization	87,315	122,999	320,039	425,927
Stock based compensation expense (income)	154,304	238,738	911,642	184,806
Bad debt expense	–	3,434	(8,633)	20,552
Total non-cash items	279,796	365,171	1,330,254	631,285
Consolidated Adjusted EBITDA (loss)	$(1,198,115)	$(2,522,552)	$(6,068,734)	$(7,586,360)

		Three months ended June 30, 2019 (unaudited)
		prior U.S. GAAP				Topic 606 impact				as reported
Statement of Operations
Revenues
Product		$	392,599			$	–			$	392,599
Service			1,681,065				(20,207	)			1,660,858
Total revenues			2,073,664				(20,207	)			2,053,457
Cost of revenues			270,883				–				270,883
Loss from operations			(1,411,425	)			(20,207	)			(1,431,632	)

		Nine months ended June 30, 2019 (unaudited)
		prior U.S. GAAP				Topic 606 impact				as reported
Statement of Operations
Revenues
Product		$	1,651,928			$	(766,192	)		$	885,736
Service			2,914,956				(84,445	)			2,830,511
Total revenues			4,566,884				(850,637	)			3,716,247
Cost of revenues			564,176				(6,668	)			557,508
Loss from operations			(6,416,455	)			(843,971	)			(7,260,426	)
Assets
Prepaids and other current assets		$	551,178			$	(6,669	)		$	544,509
Liabilities and stockholder’s equity
Deferred Revenue		$	452,139			$	350,446			$	802,585
Accumulated Deficit			(254,921,402	)			(350,446	)			(255,271,848	)

LineaRx Positioned to Benefit from Increasing Demand for Nucleic-Acid Dependent Therapies; Potential to Make Redirected Cell Therapies, such as CAR T, Faster, Safer, More Effective and with Lower Design and Manufacturing Costs

STONY BROOK, NY. August 12, 2019 – LineaRx, Inc. (“LineaRx”), a majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced that, in a decision rendered on August 7, 2019, the Centers for Medicare and Medicaid Services (CMS) approved chimeric antigen receptor (CAR) T-cell therapies that fit the CMS criteria for Medicare beneficiaries nationwide. LineaRx believes its unique method of manufacturing DNA is well poised to benefit from the increasing demand for nucleic-acid dependent therapies, like CAR T, as biotechnology companies pursue their gene and cell therapies with reimbursement assured by the CMS decision.

CAR T-based treatments involve extracting and genetically altering a patient’s T cells to attack a protein on the surface of cancer cells. The cells are then infused back into the patient. All approved CAR T and other redirected cell therapies are manufactured using DNA that is bacterially derived and then delivered to the patient’s T cells by a virus. Such plasmids-based treatments require about three weeks to grow and are acknowledged to have the potential for unintended side-effects. LineaRx offers a cleaner, potentially higher-performing alternative to plasmid DNAs with linear DNAs produced by PCR (Polymerase Chain Reaction) that are used to reprogram CAR T cells. Applications for redirected cells are broadly anticipated with more than 850 trials globally listed on clinicaltrials.gov.

“The oncology community has greeted CAR T cell therapy with extraordinary enthusiasm, but the use of these novel therapies to combat cancer has been constrained by pricing and reimbursement. With the CMS decision, redirected cell therapies are now a permanent part of the toolbox of modern medicine, and with LineaRx, we believe we have a more desirable manufacturing process than plasmids, that will enable biotech companies to accelerate their commercialization efforts,” stated Dr. James Hayward, president and CEO of LineaRx. “With the LineaRx ability to provide massive ultrapure DNA with shorter lead times than plasmids, its manufacturing technology should enable gene therapy companies to shorten time-to-market for their therapies and in a much more cost-efficient manner. Patients will also benefit by a more rapid turnaround. Moreover, we believe that our recent acquisition of Vitatex, which just closed last week, facilitates our development of redirected cell therapies by enabling us to study the lymphocytes that we capture alongside the circulating tumor cells from the blood of cancer patients. We believe these studies will guide us toward optimal design of the engager that allows CAR T cells to recognize their host’s cancer at a molecular level.”

Full text of CMS decision: Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture. Go to www.adnas.com for more information on LineaRx and to learn more about how Applied DNA makes life real and safe. LineaRx is a majority-owned Applied DNA Sciences, Inc. (Nasdaq: APDN) company.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the risk that the acquisition will not be successfully integrated with LineaRx or that the potential benefits of the acquisition will not be realized, the Company’s  history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, ability to maintain its NASDAQ listing in light of delisting notices received  and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com

NEW YORK — LineaRx said today that it has acquired the assets and intellectual property of Vitatex, a developer of invasive circulating tumor cell (iCTC) analysis technologies.

According to LineaRx — an Applied DNA Sciences subsidiary formed around technologies for DNA design, manufacture, and chemical modification by large scale PCR —  Vitatex’s technologies allows iCTCs to be isolated from standard blood samples. These cells can then be cultured and challenged against panels of cancer therapies to help personalize treatments, such as CAR T immunotherapies, for specific patients.

Following the acquisition, LineaRx said that it will work with other companies to enhance their cancer assays, generate personalized redirected cell therapies against cancers with high mutation burdens and metastatic potential, out-license Vitatex’s technologies for use in early cancer diagnostics and prognostics, and design synthetic genes to redirect immune cells against antigens that are recognized by leukocytes that comigrate with iCTCs. It also aims to develop therapeutics that use its proprietary DNA manufacturing methods.

Platform for Functional Isolation of Invasive Circulating Tumor Cells Empowers Three LineaRx Product Categories: Diagnostics, Prognostics and Therapeutics; Creates Integrated Product and Service Offering

STONY BROOK, NY. August 8, 2017 – LineaRx, Inc. (“LineaRx”), a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), announced today that it has acquired the physical assets and Intellectual Property (IP) of Vitatex Inc. (“Vitatex”), a private biotechnology company focused on advancing personalized medicine with an innovative solution that  isolates Invasive Circulating Tumor Cells (iCTCs) from standard patient blood samples. Vitatex’s solution identifies metastatic cells often before primary tumors are visible to other diagnostic technologies, when preventive care for impending cancer is still an option.

“We are honored to now include Vitatex executives on our team and employ its powerful technology within our platform,” said Dr. James Hayward, president and CEO of LineaRx. “We believe that the sophisticated technology sets us apart and integrates closely with the LineaRx service and technology offerings, broadening our addressable markets and shortening our development cycle.”

Invasive Circulating Tumor Cells (iCTCs) are isolated from the blood using Vitatex’s patented, novel functional assay that requires the cells to duplicate the metastatic behaviors of intravasation (leaving a primary tumor and initiating escape through a capillary or lymphatic vessel) and extravasation (exiting capillaries and lymphatic vessels and entering organs to form aggressive secondary tumors.) These assays are highly personalized and offer information regarding the metastatic potential of each individual’s unique cancer. The worldwide market for CTC technologies is projected to reach $17.6 billion by 2025 at a 20% CAGR over the period[1].

In contrast to competitive technologies that only recognize parts of cancer DNA, the Vitatex platform captures living cancer cells that enter the blood stream at very low rates. As such, they can be cultured and challenged against panels of cancer therapies to optimize selection of treatment tailored to each patient. Genomic information gathered from the iCTCs and associated lymphocytes that have already recognized the iCTCs as cancer can be used to target individualized cancer antigens (neoantigens) in immune therapies such as CAR T.

“We are thrilled to be joining LineaRx, whose technologies we believe will alter the future of cancer therapy. Our combined platforms offer opportunities to diagnose cancer early, personalize redirected cell therapies, and predict outcomes across many cancer indications,” stated Dr. Wen-Tien Chen, Research Professor of Medical Oncology at Stony Brook University, and the founder and president of Vitatex.

Dr. Chen, who joins LineaRx as a Consulting Emeritus Scientist and Principal Investigator, discovered the enzyme seprase while serving as Director of the Tumor Invasion and Metastasis Program at Georgetown University. Seprase is a protease (a protein-digesting enzyme) secreted at the invasive front of metastasizing cancers.  Included in the IP acquired by LineaRx, are several hybridoma cell lines, including one that produces antibodies directed against seprase. These antibodies have potential both as therapeutics as well as for characterizing iCTCs as cancerous.

Dr. Michael Pearl, Professor of Gynecological Oncology and Medical Director of the Cancer Center Clinical Trials Office at Stony Brook University Hospital, and author of multiple papers on iCTCs, stated: “Although the prevalence of ovarian cancer is very low there is a high unmet need for better therapies. As we have recently shown, the positive predictive value (PPV) of using iCTCs as a screening test for patients who are at high risk, raises the PPV to well over 97%.”LineaRx plans to work with existing companies in the diagnostic market and enhance the functionality and sensitivity of their cancer diagnostic assays. Longer term, the Vitatex platform is intended to be used to generate ultra-personalized redirected cell therapies, produced at the point of care, to cancers with high mutation burdens that also have the greatest metastatic potential. LineaRx intends to develop and out-license the technology as an early cancer diagnostic, and a prognostic to follow the course of contemporary cancer therapies including such redirected cell therapies as CAR T (T cells redirected against a patient’s cancer by an inserted nucleic acid that codes for Chimeric Antigen Receptors), and, to develop therapeutics that utilize LineaRx’s unique DNA manufacturing based upon large-scale polymerase chain reaction (PCR).

LineaRx intends to design synthetic genes to redirect immune cells against antigens that are recognized by leukocytes that comigrate with the iCTCs, one of the unique features of the Vitatex platform. Vitatex has been the beneficiary of more than $7 million of NCI funding over the course of its history, and LineaRx has already begun the application for a new contract to support commercialization, with matching funds from commercial partners. Dr. Chen continued, “We believe LineaRx has the commercial and compliance experience to bring our technologies quickly to commercial practice to aid the cancer community.”

Two senior members of the Vitatex team have joined the parent company of LineaRx, Applied DNA: Qiang Zhao, MD and Huan Dong, Ph.D. A Licensing Agreement was also signed between LineaRx and The Research Foundation for The State University of New York, since the discoveries claimed in the licensed patents were made on the campus of Stony Brook University. Peter Donnelly, Associate Vice President for Technology Partnerships for Stony Brook University stated: “We are pleased to expand our relationship with one of our community’s most productive and insightful entrepreneurs. The management at LineaRx has the experience, technical and compliance insights, and indefatigable drive to bring these technologies to market quickly.”

The acquisition of Vitatex by LineaRx was structured as an “earn-out,” allowing LineaRx to realize value before paying for it. Initial payment comprised $300,000 worth of equity in LineaRx at a valuation of $25 million for LineaRx. Subsequent payments are milestone-based, rising to a maximum of $1 million in value, comprising a total of $800,000 in LineaRx equity (based on the then-current market capitalization of LineaRx) and $200,000 in cash.

Dr. Kenneth Kaushansky, senior vice president of Health Sciences for Stony Brook University, and Dean of the Renaissance School of Medicine, and himself an expert on myeloproliferative cancers, stated: “Dr. Chen has invented and patented a fundamentally new technology for the capture and subsequent analysis of CTCs. With much excitement, we have watched the commercial progress of that technology as it has developed via multiple rounds of highly competitive SBIR funding, here at the Stony Brook University Medical Center. As have many others, we have been fascinated by the potential for such CTC-based approaches to cancer diagnostics. But arguably, what has been generally lacking in the field of CTC diagnostics is the ability to capture such CTCs based on the functional characteristics of a tumor cell, which the Vitatex technology is uniquely positioned to deliver. The recent pairing with LineaRx will provide the opportunity to take the Vitatex CTC technology to the next level, in terms of manufacturing scale-up, ISO and cGMP validation and the direct coupling of the Vitatex technology to a wide range of “best in breed” DNA-based and protein-based diagnostic assay technologies, which LineaRx already supports with its other commercial partners.”

Dr. Hayward summarized: “Dr. Chen’s lifetime contribution to the understanding of the mechanisms of cancer metastasis are inestimable. We are very fortunate to be able to work with his team to evolve and commercialize these technologies to improve the lives of cancer patients.”

[1] https://www.globenewswire.com/news-release/2019/04/26/1810526/0/en/The-Worldwide-Market-for-Circulating-Tumor-Cells-CTC-to-2025-A-17-5-Billion-Opportunity.html

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.  Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the risk that the acquisition will not be successfully integrated with LineaRx or that the potential benefits of the acquisition will not be realized, the Company’s  history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, ability to maintain its NASDAQ listing in light of delisting notices received  and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com